(Q43621463)

25 November 2017

title

Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment (English)

1 reference

25 November 2017

0 references

V Knott

1

1 reference

25 November 2017

A Labelle

series ordinal

2

1 reference

25 November 2017

B Jones

series ordinal

3

1 reference

25 November 2017

C Mahoney

series ordinal

4

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

25 November 2017

published in

Schizophrenia Research

1 reference

25 November 2017

volume

50

1 reference

25 November 2017

issue

1-2

1 reference

25 November 2017

page(s)

41-53

1 reference

Quantitative EEG in schizophrenic patients before and during pharmacotherapy

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Pretreatment EEG predicts short-term response to haloperidol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Theoretical and practical importance of plasma levels of haloperidol. correlations with clinical and computerized EEG data

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Physical aspects of the EEG in schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Intra and inter-hemispheric changes in alpha intensities in EEGs of schizophrenic patients versus matched controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG activation patterns during the performance of tasks involving different components of mental calculation.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG Profile Studies of Clozapine in Volunteers and Psychiatric Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Spontaneous motor activity in healthy volunteers after single doses of haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Topographical distribution of absolute alpha-power in the EEG and psychopathology in schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

CEEG mapping in drug-free schizophrenics. Differences from healthy subjects and changes induced by haloperidol treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

QEEG alpha 1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Schizophrenia and EEG spectral analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG mapping of left hemisphere dysfunction during motor performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Bilateral brain dysfunction during motor activation in type II schizophrenia measured by EEG mapping

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG alterations in patients treated with clozapine in relation to plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Development of a classification rule for four clinical therapeutic psychotropic drug classes with EEG power-spectrum variables of human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Qualitative and Quantitative EEG Findings in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Quantitative EEG Brain Mapping In Psychotropic Drug Development, Drug Treatment Selection, and Monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

HZI systems for EEG parametrization and classification of psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computerized EEG as a Predictor of Drug Response in Treatment Resistant Schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Letter: The epsilon-adjustment procedure for repeated-measures analyses of variance

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Clozapine increases EEG photic driving in clinical responders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Topographic analysis of EEG photic driving in patients with schizophrenia following clozapine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Quantitative electrophysiological characteristics and subtyping of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computed electroencephalographic activity mapping in schizophrenia. The resting state reconsidered

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Alpha frequency in schizophrenia: an association with enlarged cerebral ventricles

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Reliability and validity of the positive and negative syndrome scale for schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The effect of acute tryptophan depletion and fenfluramine on quantitative EEG and mood in healthy male subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Paroxysmal EEG Activity and Psychopathology During the Treatment with Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

A psychobiological model of the pathogenesis of schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Drug-Induced Paroxysmal EEG-Activities

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Saccadic eye movements in tracking, fixation, and rest in schizophrenic and normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Negative symptoms and EEG alpha activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG asymmetry in schizophrenic patients before and during neuroleptic treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG coherence in unmedicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Localization of sources of brain alpha/theta/delta activity and the influence of the mode of spontaneous mentation.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computerized EEG in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Structure and function: brain electrical activity mapping and computed tomography in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Brain electrical activity mapping (BEAM) in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Altered topography of EEG spectral content in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computed EEG in schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG coherence in unmedicated schizophrenic patients: topographical study of predominantly never medicated cases

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

QEEG profiles of psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Cognitive improvement in schizophrenia with novel antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG-brain mapping. A method to optimize therapy in schizophrenics using absolute power and center frequency values

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Quantitative EEG and BPRS data following Haldol-Decanoate administration in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Eye blink and schizophrenia: psychosis or tardive dyskinesia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Background EEG reactivity in auditory event-related potentials.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Clozapine-induced seizures and EEG changes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Slower theta activity over the midfrontal cortex in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The effects of haloperidol on the EEG spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Frontal spectral EEG findings in acutely ill schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

10.1016/S0920-9964(00)00165-1

Identifiers

DOI

1 reference

25 November 2017

1 reference